Ursolic acid protects diabetic mice against monocyte dysfunction and accelerated atherosclerosis

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 409-416

  Ullevig, Sarah L ^b   Zhao, Qingwei ^a   Zamora, Debora ^a   Asmis, Reto ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Atherosclerosis; Chemotaxis; Diabetes; Monocyte

Indexed keywords

ALBUMIN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL; CREATININE; GLUCOSE; HYDROGEN PEROXIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIGEL; MONOCYTE CHEMOTACTIC PROTEIN 1; RESVERATROL; STREPTOZOCIN; TRIACYLGLYCEROL; URSOLIC ACID;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CHEMOTAXIS; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IC 50; LIPID DIET; MACROPHAGE; MONOCYTE; MONOCYTOSIS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHYTONUTRIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; AORTIC DISEASES; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CELL LINE; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERLIPIDEMIAS; KIDNEY; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; OXIDATIVE STRESS; RECEPTORS, CCR2; RECEPTORS, LDL; STILBENES; TIME FACTORS; TRITERPENES;

EID: 82955203215     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.013     Document Type: Article

References (42)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
3. Gautier E.L., Jakubzick C., Randolph G.J. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:1412-1418.
4. Lamb R.E., Goldstein B.J. Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism insulin resistance, and vascular function. Int J Clin Pract 2008, 62:1087-1095.
5. McEwen L.N., Kim C., Haan M., et al. Diabetes reporting as a cause of death: results from the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 2006, 29:247-253.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
7. Tesch G.H. Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol 2007, 34:1016-1019.
8. Rosen P., Nawroth P.P., King G., et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001, 17:189-212.
9. Padmos R.C., Schloot N.C., Beyan H., et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes 2008, 57:2768-2773.
10. Noritake M., Katsura Y., Shinomiya N., et al. Intracellular hydrogen peroxide production by peripheral phagocytes from diabetic patients. Dissociation between polymorphonuclear leucocytes and monocytes. Clin Exp Immunol 1992, 88:269-274.
11. Ohno Y., Aoki N., Nishimura A. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993, 77:1072-1077.
12. Qiao M., Zhao Q., Lee C.F., et al. Thiol oxidative stress induced by metabolic disorders amplifies macrophage chemotactic responses and accelerates atherogenesis and kidney injury in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2009, 29:1779-1786.
13. Omar E.A., Kam A., Alqahtani A., et al. Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicals. Curr Pharm Des 2010, 16:3776-3807.
14. Hirai S., Takahashi N., Goto T., et al. Functional food targeting the regulation of obesity-induced inflammatory responses and pathologies. Mediators Inflamm 2010, 2010:367838.
15. Ikeda Y., Murakami A., Ohigashi H. Ursolic acid: an anti- and pro-inflammatory triterpenoid. Mol Nutr Food Res 2008, 52:26-42.
16. Penumathsa S.V., Thirunavukkarasu M., Zhan L., et al. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 2008, 12:2350-2361.
17. Thirunavukkarasu M., Penumathsa S.V., Koneru S., et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide thioredoxin, and heme oxygenase. Free Radic Biol Med 2007, 43:720-729.
18. Do G.M., Kwon E.Y., Kim H.J., et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008, 374:55-59.
19. Shukla Y., Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 2011, 1215:1-8.
20. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
21. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
22. Ungvari Z., Orosz Z., Rivera A., et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 2007, 292:H2417-H2424.
23. Pacholec M., Bleasdale J.E., Chrunyk B., et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010, 285:8340-8351.
24. Pervaiz S., Holme A.L. Resveratrol: its biologic targets and functional activity, antioxid. Redox Signal 2009, 11:2851-2897.
25. Yoshizaki T., Schenk S., Imamura T., et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 2010, 298:E419-E428.
26. Somova L.O., Nadar A., Rammanan P., Shode F.O. Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. Phytomedicine 2003, 10:115-121.
27. Jayaprakasam B., Olson L.K., Schutzki R.E., Tai M.H., Nair M.G. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). J Agric Food Chem 2006, 54:243-248.
28. Qiao M., Kisgati M., Cholewa J.M., et al. Increased expression of glutathione reductase in macrophages decreases atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27:1375-1382.
29. Swirski F.K., Libby P., Aikawa E., et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007, 117:195-205.
30. Sunderkötter C., Nikolic T., Dillon M.J., et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004, 172:4410-4417.
31. Mine S., Okada Y., Tanikawa T., et al. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun 2006, 344:780-785.
32. Ding Y., Kantarci A., Hasturk H., et al. Activation of RAGE induces elevated O2- generation by mononuclear phagocytes in diabetes. J Leukoc Biol 2007, 81:520-527.
33. Steinkamp-Fenske K., Bollinger L., Völler N., et al. Ursolic acid from the Chinese herb danshen (Salvia miltiorrhiza L.) upregulates eNOS and downregulates Nox4 expression in human endothelial cells. Atherosclerosis 2007, 195:e104-e111.
34. Lee C.F., Qiao M., Schröder K., Zhao Q., Asmis R. Nox4 is a novel inducible source of reactive oxygen species in monocytes and macrophages and mediates oxidized low density lipoprotein-induced macrophage death. Circ Res 2010, 106:1489-1497.
35. Liu J., Liu Y., Mao Q., Klaassen C.D. The effects of 10 triterpenoid compounds on experimental liver injury in mice. Fundam Appl Toxicol 1994, 22:34-40.
36. Jang S.M., Kim M.J., Choi M.S., Kwon E.Y., Lee M.K. Inhibitory effects of ursolic acid on hepatic polyol pathway and glucose production in streptozotocin-induced diabetic mice. Metabolism 2010, 59:512-519.
37. Zhou Y., Li J.S., Zhang X., et al. Ursolic acid inhibits early lesions of diabetic nephropathy. Int J Mol Med 2010, 26:565-570.
38. Wang Z.H., Hsu C.C., Huang C.N., Yin M.C. Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice. Eur J Pharmacol 2010, 628:255-260.
39. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
40. Frighetto R.T.S., Welendorf R.M., Nigro E.N., Frighetto N., Siani A.C. Isolation of ursolic acid from apple peels by high speed counter-current chromatography. Food Chem 2008, 106:767-771.
41. Kondo M., MacKinnon S.L., Craft C.C., et al. Ursolic acid and its esters: occurrence in cranberries and other Vaccinium fruit and effects on matrix metalloproteinase activity in DU145 prostate tumor cells. J Sci Food Agric 2011, 91:789-796.
42. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995, 49:57-68.